Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Unmet needs and future questions in cellular therapy for myeloma

Adam Cohen • 26 Aug 2022
IMS 2022
Multiple Myeloma CAR-T

Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA, highlights key unmet needs in cellular therapy for multiple myeloma, including the need to improve manufacturing processes and patient responses, as well as better mitigate toxicities associated with CAR-T products. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Adam Cohen

CARTITUDE-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma 1:45
CARTITUDE-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
Adam Cohen • 26 Aug 2022
An update on cohort C from the CARTITUDE-2 trial 2:01
An update on cohort C from the CARTITUDE-2 trial
Adam Cohen • 26 Aug 2022
CARTITUDE update: Patient expectations and experiences of cilta-cel in R/R myeloma 3:15
CARTITUDE update: Patient expectations and experiences of cilta-cel in R/R myeloma
Adam Cohen • 10 Dec 2020
Phase I trial of a FcRH5-targeted BiTE in R/R myeloma 6:44
Phase I trial of a FcRH5-targeted BiTE in R/R myeloma
Adam Cohen • 10 Dec 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals